US biopharma Apellis Pharmaceuticals (Nasdaq: APLS) closed 13% higher at the end of Wednesday’s trading after announcing longer-term data from the Phase III DERBY and OAKS studies.
The data showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for the treatment of GA secondary to age-related macular degeneration (AMD).
"These results reinforce the potential of pegcetacoplan to become the first-ever treatment for patients with this debilitating disease"These data will be included in the New Drug Application (NDA) that Apellis plans to submit to the US Food and Drug Administration (FDA) in the second quarter of 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze